Regeneron Pharmaceuticals, Inc.
REGN · Healthcare · Biotechnology
Updated 27 min ago · data delayed ≥15 min
IconicScore
ProprietaryRanked #153 of 500 by Iconic Score · #21 of 59in its sector. IconicAlpha’s proprietary brand-intelligence metric — a multi-model blend of scale, market attention, category leadership, and AI-analyzed brand visibility.
Get the free morning email
The biggest IconicScore™ gainer and loser, plus the strongest and weakest sectors, in your inbox before the open. See a sample →
Price performance
Export history · AnalystThis insight is part of the Analyst tier — unlock the IconicScore vs. price overlay, side-by-side comparison, and CSV export.
Upgrade to AnalystThis is part of the Enterprise tier — benchmark your IconicScore against sector peers, claim your profile, and manage how your brand appears on the wall.
Upgrade to EnterpriseIconic Profile
Regeneron Pharmaceuticals Inc (REGN) is a leading biotechnology company focused on the discovery, development, and commercialization of innovative medicines for serious medical conditions. With a market capitalization of $70.7 billion, Regeneron is recognized for its robust pipeline of therapies, including treatments for eye diseases, cancer, and inflammatory conditions. The company’s flagship products, such as EYLEA and Dupixent, have established strong market positions, contributing significantly to its revenue and growth. Regeneron’s commitment to scientific research and development, along with its strategic partnerships, enhances its competitive edge in the biotechnology sector. As a key player in healthcare, Regeneron is poised to address unmet medical needs and drive advancements in patient care, making it a notable entity in the evolving landscape of biopharmaceuticals.
IconicOracleAI™ Brief
Regeneron Pharmaceuticals Inc currently holds an Iconic Score of 54, reflecting moderate brand strength amid competitive pressures highlighted in recent headlines. The company's market cap stands at $83.5 billion, with a slight price decline of 0.22%. Brand visibility remains strong at 85/100, indicating effective logo recognition, though discussions around overvaluation compared to rivals may be influencing investor sentiment.
AI-generated explanation of current score drivers. Not investment advice.
Enterprise tier: claim your logo to manage how your brand is represented.